Cargando…
Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarba...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849672/ https://www.ncbi.nlm.nih.gov/pubmed/29476231 http://dx.doi.org/10.1007/s00216-018-0889-x |
_version_ | 1783306077964599296 |
---|---|
author | Pelivan, Karla Frensemeier, Lisa M. Karst, Uwe Koellensperger, Gunda Heffeter, Petra Keppler, Bernhard K. Kowol, Christian R. |
author_facet | Pelivan, Karla Frensemeier, Lisa M. Karst, Uwe Koellensperger, Gunda Heffeter, Petra Keppler, Bernhard K. Kowol, Christian R. |
author_sort | Pelivan, Karla |
collection | PubMed |
description | Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarbazones, was investigated in more than 30 clinical phase I/II trials, but the results against solid tumors were disappointing. Recent investigations from our group suggested that this is, at least partially, based on the fast metabolism and excretion. In order to establish more detailed structure/activity/metabolism relationships, herein a panel of 10 different Triapine derivatives was investigated for their metabolic pathways. From the biological point of view, the panel consists of terminally dimethylated thiosemicarbazones with nanomolar IC(50) values, derivatives with micromolar cytotoxicities comparable to Triapine and a completely inactive representative. To study the oxidative metabolism, a purely instrumental approach based on electrochemistry/mass spectrometry was applied and the results were compared to the data obtained from microsomal incubations. Overall, the investigated thiosemicarbazones underwent the phase I metabolic reactions dehydrogenation, hydroxylation, oxidative desulfuration (to semicarbazone and amidrazone) and demethylation. Notably, dehydrogenation resulted in a ring-closure reaction with formation of thiadiazoles. Although strong differences between the metabolic pathways of the different thiosemicarbazones were observed, they could not be directly correlated to their cytotoxicities. Finally, the metabolic pathways for the most cytotoxic compound were elucidated also in tissues collected from drug-treated mice, confirming the data obtained by electrochemical oxidation and microsomes. In addition, the in vivo experiments revealed a very fast metabolism and excretion of the compound. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00216-018-0889-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5849672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-58496722018-03-21 Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones Pelivan, Karla Frensemeier, Lisa M. Karst, Uwe Koellensperger, Gunda Heffeter, Petra Keppler, Bernhard K. Kowol, Christian R. Anal Bioanal Chem Research Paper Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarbazones, was investigated in more than 30 clinical phase I/II trials, but the results against solid tumors were disappointing. Recent investigations from our group suggested that this is, at least partially, based on the fast metabolism and excretion. In order to establish more detailed structure/activity/metabolism relationships, herein a panel of 10 different Triapine derivatives was investigated for their metabolic pathways. From the biological point of view, the panel consists of terminally dimethylated thiosemicarbazones with nanomolar IC(50) values, derivatives with micromolar cytotoxicities comparable to Triapine and a completely inactive representative. To study the oxidative metabolism, a purely instrumental approach based on electrochemistry/mass spectrometry was applied and the results were compared to the data obtained from microsomal incubations. Overall, the investigated thiosemicarbazones underwent the phase I metabolic reactions dehydrogenation, hydroxylation, oxidative desulfuration (to semicarbazone and amidrazone) and demethylation. Notably, dehydrogenation resulted in a ring-closure reaction with formation of thiadiazoles. Although strong differences between the metabolic pathways of the different thiosemicarbazones were observed, they could not be directly correlated to their cytotoxicities. Finally, the metabolic pathways for the most cytotoxic compound were elucidated also in tissues collected from drug-treated mice, confirming the data obtained by electrochemical oxidation and microsomes. In addition, the in vivo experiments revealed a very fast metabolism and excretion of the compound. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00216-018-0889-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-02-23 2018 /pmc/articles/PMC5849672/ /pubmed/29476231 http://dx.doi.org/10.1007/s00216-018-0889-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Paper Pelivan, Karla Frensemeier, Lisa M. Karst, Uwe Koellensperger, Gunda Heffeter, Petra Keppler, Bernhard K. Kowol, Christian R. Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title | Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title_full | Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title_fullStr | Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title_full_unstemmed | Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title_short | Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones |
title_sort | comparison of metabolic pathways of different α-n-heterocyclic thiosemicarbazones |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849672/ https://www.ncbi.nlm.nih.gov/pubmed/29476231 http://dx.doi.org/10.1007/s00216-018-0889-x |
work_keys_str_mv | AT pelivankarla comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT frensemeierlisam comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT karstuwe comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT koellenspergergunda comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT heffeterpetra comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT kepplerbernhardk comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones AT kowolchristianr comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones |